cerebral vascular disease 4

world federation of neurology 11th salzburg conference

> j.s. meyer, h. lechner, m. reivich and e.o. ott

CEREBRAL VASCULAR DISEASE 4

Proceedings of the World Federation of Neurology 11th International Salzburg Conference, September 23-25, 1982

Editors:

J.S. MEYER, H. LECHNER, M. REIVICH and E.O. OTT



© 1983, Elsevier Science Puslishers B.V., Amsterdam

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without permission in writing from the publisher.

International Congress Series No. 616

ISBN Excerpta Medica 90 219 0616 3 ISBN Elsevier Science Publishing Co. 0 444 90314 3

Library of Congress Cataloging in Publication Data

International Salzburg Conference (11th: 1982) Cerebral vascular disease, 4.

(International congress series; no. 616)
Includes bibliographical references and index.
1. Cerebrovascular disease--Congresses. I. Meyer,
John Stirling. II. World Federation of Neurology.
III. Title. IV. Series.
RC388.5.I514 1982 616.8'1 83-5639
ISBN 0-444-90314-3 (Elsevier)

Publisher: Excerpta Medica 305 Keizersgracht P.O. Box 1125 1000 BC Amsterdam

Sole Distributors for the USA and Canada: Elsevier Science Publishing Co. Inc. 52 Vanderbilt Avenue New York, N.Y. 10017

INTERNATIONAL SALZBURG CONFERENCE ON CEREBRAL VASCULAR DISEASE

founded by

H. BERTHA, O. EICHHORN, H. LECHNER

organized by

FEDERATION MONDIALE DE NEUROLOGIE WORLD FEDERATION OF NEUROLOGY

Research Group on Cerebrovascular Disease

Executive Committee:

SIR JOHN WALTON, Newcastle, Chairman of the Research Committee, ex officio

A. LOWENTHAL, Wilrijk, Secretary of the Research Committee, ex officio

D. KLEIN, Geneva, Treasurer of the Research Committee, ex officio

A. AGNOLI, Rome

A. BES, Toulouse H. v.d. DRIFT, Amsterdam

F. GOTOH, Tokyo

H. LECHNER, Graz

C. LOEB, Genova

J. MARSHALL, London

J.S. MEYER, Houston

E. OTT, Graz M. REIVICH, Philadelphia

L. SYMON, London

F. TORRES, Minneapolis

Secretaries of the Research Group:

H. LECHNER, Graz

C. LOEB, Genova

J. MARSHALL, London

J.S. MEYER, Houston

GENERAL COMMENTS

Fifty-three papers were selected for presentation by 231 listed authors and co-authors at the Salzburg Conference. Authors were from Austria, Canada, Denmark, UK, Finland, France, Holland, India, Italy, Japan, Norway,

Peru, USA, West Germany.

The topics included: In vivo measurements of cerebral blood flow and metabolism, Aging and risk factors influencing cerebral blood flow and incidence of stroke, Platelet aggregation in patients with transient ischemic attacks (TIA) and reversible ischemic neurological deficits (RIND), Autoregulation of cerebral blood flow, Neurogenic hyperand hypo-tension in vertebral basilar arterial ischemia, Cerebral embolism, Nuclear magnetic imaging in cerebrovascular disease, Multi-dimensional analysis for predicting prognosis in stroke, Ultrasonic scanning and digital subtraction, Intravenous angiography in cerebrovascular disease, Anti-platelet aggregation, Treatment in cerebro-vascular disease, Hemodilution as a treatment for stroke, Calcium (Ca2+) entry blockers in cerebral infarction, International extracranial-intracranial (EC/IC) by-pass study, Total microsurgical excision of cerebral AVMs, Role of aneurysmal size to rupture of aneurysms, CT scans, Assessment of neurologically silent strokes and multiinfarct dementia (MID), Cerebral blood flow in dementia, Evidence for neuroplasticity after experimental infarction, and New concepts of cerebrovascular mechanisms in migraine.

The consensus was that this was a valuable meeting with an excellent opportunity to review "state of the art" developments in methodology, exchange new information and participate in the ample time provided for discussion. The meeting was opened by Dr. Helmut Lechner (Graz, Austria), the organizing secretary and by the Chairman, Dr. John Marshall (UK).

CONTENTS

BERTHA MEMORIAL LECTURE

Measurement of local cerebral glucose utilization: its use in localizing normal and abnormal func- tional activities in the nervous system. L. Sokoloff	3
I. REGULATION OF CEREBRAL BLOOD FLOW AND RISK FACTORS	
Four year longitudinal (prospective) analysis of age related changes in cerebral blood flow measured in normal healthy and risk factored volunteers. T.G. Shaw, K.F. Mortel, J.S. Meyer, Jeff Hardenberg, T. Okabe and H. Okayasu	15
Hospital incidence of cerebro-vascular diseases in high altitude. E. Bancalari, J. Galvez-Brandon, M. Vasquez and E. Marticorena	22
Circulating platelet aggregates in 191 RIA patients and 117 control subjects. M. Prencipe, C. Buttinelli, S. Paolucci, C. Fieschi, G. Lucignani and G.L.Lenzi	
Enhanced red cell aggregation and reduced red cell deformability in patients with cerebrovascular disease. E. Ott, H. Lechner, F. Fazekas, M. Tschinkel and R. Schröer	35
Transient hyperemic attack. F. Gotoh, F. Muramatsu, Y. Fukuuchi, T. Amano, H. Okayasu, K. Tanaka, N. Suzuki and M. Kobari	39
The extent of autoregulation impairment in acute ischemic stroke - in man. M. Hommel, A. Guell and A. Bes	45
The vertebral arterial system in rhesus monkeys is less efficient in autoregulation of blood flow than the internal carotid arterial system. M. Tomita, F. Gotoh, T. Sato, N. Tanahashi, K. Tanaka and M. Kobari	48
Transient neurogenic hypertension in relation to persistent neurogenic hypotension in vertebro-basilar (V.B.) ischaemia. J.H.A. van der Drift	53
Carotid artery embolism. P.M. Dalal	61

II. NEUROIMAGING TECHNIQUES

Proton (1H) NMR imaging in cerebral infarction. F.S. Buonanno, I.L. Pykett, J.P. Kistler, T.J. Brady, K. Davis, C.T. Burt, W.S. Hinshaw, M.R. Goldman and G.M. Pohost	71
Use of ¹¹ C-deoxyglucose for the measurement of local cerebral glucose metabolism in humans. M. Reivich, A. Alavi, A. Wolf and J.H. Greenberg	76
<pre>Xenon-133 and isopropyl-amphetamine iodine-123 studies of brain blood flow in man by single photon tomo- graphy. N.A. Lassen, L. Henriksen, S. Holm, D. Barry, O.B. Paulson, S. Vorstrup, J. Rapin, M. le Poncin-Lafitte and J.L. Moretti</pre>	81
Regional multi-parametric assessment of brain tumors and brain infarcts. W. Paschen, G. Mies, W. Bodsch and KA. Hossmann	86
A dynamic concept of acute cerebral infarction based on studies of rCBF, cerebral angiography, CT-scan and isotope brain scintigraphy. T. Skyhøj Olsen and N.A. Lassen	91
Multidimensional analysis for predicting recovery from cerebrovascular diseases - analysis on putaminal hemorrhage. F. Sakai, Y. Tazaki, T. Kanda, N. Furuhashi, H. Hino, N. Kitai, H. Asakura, K. Sakurai, Y. Takagi and M. Takagi	96
Ultrasonic duplex scanning and digital subtraction angiography in the assessment of carotid bifurcation disease. F.L. Moll, B.C. Eikelboom, F.E.E. Vermeulen, A.R. de Vries, R.G.A. Ackerstaff and B.P.M. Schulte	00
Correlation between digital angiography and doppler- sonography in 25 patients with ischemic distur- bances in the carotid territory. C. Fieschi, P. Fiorani, P. Rossi, A. Carolei, P. Laglia, F. Passarelli, R. Passariello, G. Simonetti, C. Spartera and E. Zanette	03
Doppler velocimetry and intravenous angiography for diagnosing extracranial atheromatous lesions. P. Celsis, M. Ducos de Lahitte, M. Clanet, G. Viallard, J.P. Ponsaille, A. Rascol and J.P.	
	06

III. CRITICAL EVALUATION OF THERAPEUTIC APPROACHES

Assessment of mechanisms and drugs controlling platelet aggregation in cerebral vessels. W.I. Rosenblum	113
The french "A.I.C.L.A." randomized trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral infarction. M.G. Bousser, E. Eschwege, M. Haguenau, J.M. Lefauconnier, N. Thibult, D. Touboul and P.J. Touboul	118
Effects of low VS high dosages of aspirin on platelet aggregation in patients with cerebrovascular disease - a follow up study C. Loeb, U. Armani, C. Gandolfo, N. Dagnino, M. Giunchedi, A. Piana, A. Piccardo, G.A. Ottonello and P. Tanganelli	122
Minimal dosage of acetylsalicylic acid needed for platelet inhibition in patients with cerebrovascular disease. G. Boysen, J. Bøttcher and J.S. Olsen	131
Ticlopidine hydrochloride: a new approach to stroke prevention after TIA. W.K. Hass, J.J. Bruno, B.A. Molony, B. Kamm and J.D. Easton	134
Effect of different antiplatelet drugs on circulating platelet aggregates in RIA patients. S. Paolucci, C. Buttinelli, M. Prencipe, C. Fieschi, G. Lucignani and A. Carolei	138
Blood viscosity and cerebral blood flow. M.M. Brown and J. Marshall	143
Ischemic stroke treated by haemodilution. An interim report of a randomized trial. K. Asplund, S. Eriksson, E. Hägg, F. Lithner, T. Strand and P.O. Wester	148
The effects of a calcium antagonist, upon the patho- physiology of cerebral ischaemia. L. Symon, R.J. Harris and N.M. Branston	151
Decreased glucose metabolism in functionally inactivated brain regions in ischemic stroke and its alteration by activating drugs. W.D. Heiss, H.W. Ilsen, R. Wagner, G. Pawlik, K. Wienhard and L. Eriksson	162
International EC/IC bypass study. H.J.M. Barnett	168
Haemodynamic events and failure of the extra-	, 50
intracranial arterial anastomosis. G. Maira, G.F. Rossi, A. Vignati, C. Anile, E. Fernandez, A. Agnoli and S. Ruggieri	169

Cerebral blood flow before and after reconstructive vascular surgery in patients with TIA by 133-Xenon inhalation tomography. S. Vorstrup, R. Hemmingsen, L. Henriksen, H. Lindewald and N.A. Lassen	177
Extracranial/intracranial bypass surgery: technique or therapy? V. Hachinski	182
Xenon enhanced CT scanning before and after excision of cerebral AVMs - Contribution to pathogenesis and treatment. T. Okabe, J.S. Meyer, H. Okayasu, R. Harper, J. Rose, R. Grossman, R. Centeno and Y. Yen Lee	185
The role of aneurysmal size in subarachnoid hemorrhage. N.F. Kassell, C. James and M.S. Torner	194
IV. CEREBRAL PERFUSION AND METABOLISM IN RELATION TO FUNCTION	
The relationship of regional cerebral blood flow, oxygen metabolism and glucose metabolism in acute stroke. R.J.S. Wise, C.G. Rhodes, J. Gibbs, J. Hatazawa, R.S.J. Frackowiak and T. Jones	199
Measurement of local blood flow and oxygen con- sumption in evolving irreversible cerebral in- farction: an in vivo study in man. J.C. Baron, D. Rougemont, P. Lebrun-Grandié, M.G. Bousser, E. Cabanis, J. Bories, D. Comar and P. Castaigne	205
The neurologically silent stroke and its clinical relevance. G. Ladurner, W.D. Sager and L.D. Iliff	213
Relationship of cerebral blood flow to metabolism in acute head injury. W.D. Obrist, J.L. Jaggi, D.L. Steiman and J. Cruz	221
Evolution of the hyperfrontal distribution of rCBF in advancing age. P. Meric, H. Mamo, A. Luft and J. Seylaz	226
Hyperfrontal distribution of grey matter flow studied by 133 Xenon inhalation: results in normal subjects, in aging and parkinsonism. A. Bes, A. Guell, N. Fabre, G. Geraud and V. Larrue	231
A clinical approach to vascular (multiinfarct) dementia. G. Ladurner, L.D. Iliff, W.D. Sager and H. Lechner	236
Measurements of local cerebral blood flow and Xenon partition coefficients in Alzheimer's disease versus normal aging. T. Amano, J.S. Meyer,	24%

Operant learning, cerebral blood flow and neuro- histology in meriones unguiculatus after uni- lateral carotid artery ligation. H.W. Bothe, H.J. Bosma, H. Hofer, K.A. Hossmann and W.F. Angermeier	250
Concentrations of the neurotransmitters Dopamine, Noradrenaline, Serotonin and their metabolites in brain cortex of dogs in arterial normotension and moderate hypotension in relation to glucose and energy metabolism. I. Degrell, G. Stock, K. Zenner, K. Wiedemann and S. Hoyer	256
Cortical flow in relation to neuronal loss in peri- infarct tissue. G. Mies, L.M. Auer, G. Ebhardt, H. Traupe, W.D. Heiss and M. Sato	260
V. MIGRAINE	
Cerebrovascular endothelial 5-HT: new aspects of its role in migraine. M. Spatz, C.H. Maruki and J. Bembry	267
Chronic paroxysmal hemicrania (CPH). O. Sjaastad, C. Saunte, J. Aasly and H. Breivik	268
Regional cerebral blood flow by 133-Xenon inhalation and emission computerized tomography during common and classical migraine attacks. M. Lauritzen and J. Olesen	270
Platelet sensitivity and cerebral blood flow in migraine. H. Lechner, E. Ott, F. Fazekas, K. Marguc and E. Pilger	274
The spreading reduction of regional cerebral blood flow in classical migraine. M. Lauritzen, T. Skyhøj Ölsen and O.B. Paulson	278
The trigeminal nerve as a controllor of the facial and cranial vasomotor activity. The role of peptides. A. Agnoli, M. de Marinis, N. Martucci, L. Conti, F. Gagliardi and M. Nardi	282
Noradrenergic nervous dysfunction in migraine. S. Komatsumoto, F. Gotoh, N. Araki and S. Gomi	286
Ischemic strokes temporally related to migraine attacks: the EEG and the HEN. J.M. Orgogozo, P.Y. Henry, R. Pellerin and P. Loiseau	292
List of contributors	297
Author index	309

...

BERTHA MEMORIAL LECTURE

此为试读,需要完整PDF请访问: www.ertongbook.com

L. Sokoloff

Laboratory of Cerebral Metabolism, NIMH, Bethesda, MD 20205. Bertha Memorial Lecture, International Salzburg Conference on Cerebrovascular Disease, September 1982

The brain is a complex, heterogeneous organ composed of an almost infinite number of structural and functional components with widely different and independently requlated levels of functional and metabolic activities. In most tissues that do physico-chemical work, there is a close relationship between the level of functional activity and the rate of energy metabolism. Under most normal circumstances glucose is the almost exclusive substrate for the brain's energy metabolism, and its rate of utilization is a reasonable measure of the energy metabolism of cerebral tissue. A method has been developed for the quantitative determination of the rates of glucose utilization simultaneously in all the structural and functional components of the nervous system. The method is applicable to normal conscious animals as well as those in experimentally altered states of cerebral activity. The results of a number of studies with this method have demonstrated that there is in the nervous system a close coupling between the level of local functional activity and the local rate of energy metabolism (9).

The method utilizes tracer doses of radioactive 2deoxy-D-glucose to trace glucose metabolism. This analogue of glucose shares and competes with glucose for the carrier that transports them bi-directionally across the bloodbrain barrier. It also competes with glucose for hexokinase, the enzyme that phosphorylates both to their respective hexose-6-phosphates. Once formed, glucose-6-phosphate is rapidly converted to fructose-6-phosphate and metabolized further ultimately to CO2 and H2O. In contrast, 2deoxyglucose-6-phosphate, which lacks a hydroxyl group on the second carbon position, cannot be converted to fructose-6-phosphate. It is also a poor substrate for glucose-6-phosphate dehydrogenase and other enzymes in brain that act upon glucose-6-phosphate. It is hydrolyzed very slowly because of very low deoxyglucose-6-phosphatase activity in brain. Deoxyglucose-6-phosphate, once formed, is, therefore, essentially trapped in the cells, at least for a reasonable amount of time, and the amount accumulated is a measure of the amount of deoxyglucose that has been phosphorylated. The amount of deoxyglucose phosphorylated

is in turn related to the amount of glucose phosphorylated over the same interval of time, depending on the relative concentrations of the competing substrates for hexokinase and the Michaelis-Menten constants of the enzyme for the two substrates. In a steady state, the net rate of glucose phosphorylation by hexokinase is equal to the rate of glucose utilization.

A kinetic model based on these biochemical properties of 2-deoxyglucose and glucose in brain has been constructed and mathematically analyzed to derive an operational equation that permits the calculation of the local rates of cerebral glucose utilization from measurable variables (Fig. 1) (12).

The equation requires the measurement of the time courses of the arterial plasma deoxyglucose and glucose concentrations for a period of 30-45 minutes following an intravenous pulse of [14c] deoxyglucose and the final tissue concentrations of [14c]. It also requires values for the rate constants of the transport of deoxyglucose across the blood-brain barrier and its phosphorylation by hexokinase and also a combination of six constants, the so-called "lumped constant", which is a combination of the ratios of the Km and Vm values of hexokinase for deoxyglucose and glucose and also the ratio of their distribution spaces in the tissue. These constants have been determined separately in other groups of animals, and they can then be used in the equation for experiments in animals of the same species (11).

The local \$14C\$ concentrations in the tissues are determined by quantitative autoradiography of 20 \$\mu\$m serial sections of frozen brain tissue. Local tissue \$14C\$ concentration can be determined from the optical density of the structure in the autoradiograph and a calibration curve relating optical density to concentration obtained from the autoradiographic images of calibrated \$14C\$ plastic standards. The procedure of the method is so designed that the autoradiographs reflect mainly the concentrations of \$[14C]\$ deoxyglucose-6-phosphate in the cerebral tissues; they are, therefore, essentially pictorial representations of the relative rates of local glucose utilization throughout the brain.

Quantitative analysis of the autoradiographs has been greatly facilitated by the application of computerized image-processing techniques (1). The autoradiographs are automatically scanned under computer control, and the optical density of each spot on the film, from 25 to 100 µm as selected, is digitized and stored in the computer. After the plasma [14c] deoxyglucose and glucose concentrations are entered by the operator, the computer converts the optical density of each spot into concentration and then into the local rate of glucose utilization. The autoradiographs are then reconstructed and displayed in color on the face of a color-TV monitor along with a calibrated color scale. The colors represent the rates of glucose

PLASMA		BRAIN TISSUE			
	1	Precursor Pool	Metabolic Products		
[14C] Deoxyglucose (Cp) Glucose (Cp)		#; [14C]Deoxyglucose (C _E)	(CM) (4C)Deoxyglucose-6-Phosphate (CM) CONCENTRATION - Ci - Ci + CM		
Glucose = (C _P)	K2 COO'R	Glucose (C _E)	Glucose-6-Phosphate (C _M) CO ₂ · H ₂ O		

В

Functional Anatomy of the Operational Equation of the

[14C] Deoxyglucose Method

General Equation for Measurement of Reaction Rates with Tracers:

Rate of Reaction = Labeled Product Formed in Interval of Time, O to T

Solope Effect Integrated Specific Activity
of Precursor

Operational Equation of [1*C] Deoxyglucose Method:




Figure 1. (A): Diagrammatic representation of the theoretical model. C** represents the total \$^{14}\$C concentration in a single homogeneous tissue of the brain. C** and C** represent the concentrations of $[^{14}$C]$ deoxyglucose and glucose in the arterial plasma, respectively; C** and C** represent their respective concentrations in the tissue pools that serve as substrates for hexokinase. C** represents the concentration of $[^{14}$C]$ deoxyglucose-6-phosphate in the tissue. The constants k**, k***, and k** represent the rate constants for carrier-mediated transport of $[^{14}$C]$ deoxyglucose from plasma to tissue, for carrier-mediated transport back from tissue to plasma, and for phosphorylation by hexokinase, respectively. The constants k**1, k**2, and k**3 are the equivalent rate constants for glucose.

[14c] Deoxyglucose and glucose share and compete for the carrier that transports both between plasma and tissue and for hexokinase which phosphorylates them to their respective hexose-6-phosphates. The dashed arrow represents the possibility of glucose-6-phosphate hydrolysis by glucose-6-phosphatase activity, if any (10,12).

(B): Operational equation of radioactive deoxyglucose method and its functional anatomy. T represents the time at the termination of the experimental period; λ equals the ratio of the distribution space of deoxyglucose in the tissue to that of glucose; ϕ equals the fraction of glucose which, once phosphorylated, continues down the glycolytic pathway; and K_m^* and V_m^* and V_m and V_m represent the familiar Michaelis-Menten kinetic constants of hexokinase for deoxyglucose and glucose, respectively. The other symbols are the same as those defined in Figure 1A (10).

utilization, and the rate of glucose utilization of any $25\text{--}100\,\mu\text{m}$ spot in the displayed image of the brain section can be identified from its color. These pictorial displays represent, therefore, color-coded maps of the local rates of glucose utilization throughout the brain.

Rates of local cerebral glucose utilization have been determined quantitatively most frequently in the rat and monkey (Table 1).

The rates in the conscious rat vary widely throughout the brain with values in white matter ranging between 30 and 40 µmoles/100g/min and values in gray matter several fold higher, between approximately 50 and 200 µmoles/100g/min (12). The highest values are found in components of the auditory system with the inferior colliculus clearly the most metabolically active structure in the brain. The rates of glucose utilization in the conscious monkey are similarly distributed, but they are generally one-third to one-half of the values obtained in corresponding regions of the rat brain (5). The differences between the rates in the rat and monkey brains are consistent with the smaller cells more densely packed in the rat brain than in the monkey brain.

The results of numerous studies on the effects of experimentally induced focal alterations of functional activity on local cerebral glucose utilization have demonstrated a close coupling between local functional activity and energy metabolism in the nervous system (9). The effects are often so pronounced that they can be visualized directly in the autoradiographs, or even more so in the color-coded, quantitative, reconstructed maps of cerebral energy metabolism. For example, unilateral electrical stimulation of the sciatic nerve in anesthetized rats increases glucose utilization in the ipsilateral gray matter of the appropriate segments of the spinal cord.

TABLE 1. Representative values for local cerebral glucose utilization in the normal conscious albino rat and monkey $(\mu \, \text{moles}/100 \, \text{g/min})$

Structure	* Albino	Rat(10)	+ Monkey(7)
	Gray Mat	ter	
Visual Cortex Auditory Cortex Parietal Cortex Sensory-Motor Cortex Thalamus: Lateral Nucleus Thalamus: Ventral Nucleus Medial Geniculate Body Lateral Geniculate Body Hypothalamus Mamillary Body Hippocampus Amygdala Caudate-Putamen Nucleus Accumbens Globus-Pallidus Substantia Nigra Vestibular Nucleus Cochlear Nucleus Superior Olivary Nucleus Inferior Colliculus Superior Colliculus Pontine Gray Matter Cerebellar Cortex Cerebellar Nuclei			59
Corpus Callosum Internal Capsule Cerebellar White Matter	White Mat 40 ± 33 ± 37 ±		11 + 1 13 \(\frac{1}{2} \) 1 12 \(\frac{1}{2} \) 1

The values are the means + standard errors from measurements made in the number of animals indicated in parentheses.

Focal seizures induced by injection of penicillin into the motor cortex of one side of the monkey brain elicit increased glucose utilization in discrete regions of the ipsilateral motor cortex, putamen, globus pallidus, thalamic nuclei, substantia nigra, etc. Bilateral obstruction of the auditory canals in conscious rats markedly diminishes glucose utilization bilaterally in all components of the auditory system; with unilateral obstruction some structures are affected only ipsilaterally, some bilaterally, and some only contralaterally; with quantification it

^{*} Sokoloff et al. (12)

⁺ Kennedy et al. (5).